Please assess the completion status of the following clinical trial:

Trial Title: Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of multiple sclerosis, known or suspected diagnosis of glioma, or known or suspected diagnosis of cerebral metastasis~* Scheduled or to be scheduled for a follow-up MRI per standard of care for their disease~* Minimum permitted time intervals from prior treatments are 6 weeks for intracranial surgery~* Adequate renal function (serum creatinine =\< 1.5 mg/dL)~* Subject must sign a study-specific informed consent~Exclusion Criteria:~* Medically unstable~* Renal impairment (glomerular filtration rate \[GFR\] \< 60 mL/min/1.73m\^2) or history of existing nephrogenic systemic fibrosis (NSF)~* Cardiac pacemaker~* A serious concurrent infection, illness, or medical condition~* Subjects with any surgical clip, external clips, or any other ferromagnetic device, that is contraindicated for use in MRI~* Subject is claustrophobic and cannot cooperate for the MRI~* Females who are pregnant or nursing~* Any other condition that would compromise the scan with reasonable safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI) (Type: EXPERIMENTAL): Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).